SPOTLIGHT -
New Product Newswire for Oct. 20, 2003
FDA Approves First Oral Treatment for Patients With Moderate to Severe Crohn's Disease
The approval of Rinvoq (upadacitinib) was based on the results of three clinical trials: two induction therapy studies and one maintenance study.
Episode 8: Stay in Sync with Innovations in Medication Decision Support
Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.
FDA Approves Qalsody, First-of-its-Kind Treatment for Rare Form of ALS
The drug treats amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS).
FDA Approves Ruxolitinib Cream 1.5% to Treat Nonsegmental Vitiligo
Ruxolitinib (Opzelura) cream is the first and only FDA-approved treatment for patients with vitiligo.
Top Pharmacy Innovations of 2021
From medication to legislation, multiple developments have advanced the pharmacy profession this year.
Merck, Ridgeback Announce EUA Submission for Investigational Oral Antiviral Molnupiravir for COVID-19
Merck and Ridgeback Biotherapeutics have announced their submission of an EUA application to the FDA for an oral antiviral medication for the treatment of COVID-19.
